SCO­TUS to re­view Am­gen-Sanofi patent bat­tle as a proxy for how nar­row­ly phar­ma patents will need to be writ­ten

The Supreme Court has agreed to take up a long-run­ning patent bat­tle be­tween PC­SK9 fron­trun­ners Am­gen and Sanofi that has spilled in­to a broad­er is­sue of how nar­row­ly phar­ma patents should be writ­ten.

The de­ci­sion means the high­est court in the US agrees to ad­dress what’s re­ferred to as the “en­able­ment” re­quire­ment, which es­sen­tial­ly spells out how a patent should in­clude both a writ­ten de­scrip­tion of an in­ven­tion, and the man­ner and process of mak­ing and teach­ing skilled ar­ti­sans “to make and use” the in­ven­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.